Deutsche Bank AG Initiates Coverage of AtaiBeckley

NEW YORK – Deutsche Bank AG has begun formal research coverage of AtaiBeckley Inc., the Nasdaq-listed biopharmaceutical company created from the merger of atai Life Sciences and Beckley Psytech.

David Hoang, a senior equity research analyst at Deutsche Bank who focuses on publicly traded companies in the healthcare and biotech sectors, assigned a ‘Buy’ rating and a $12 price target to the AtaiBeckley stock. The research reflects the bank’s evaluation of the company’s portfolio of investigational treatments for mental health conditions often resistant to standard therapies.

AtaiBeckley’s programs include BPL-003, a nasal spray formulation of mebufotenin (5-MeO-DMT) for treatment-resistant depression (TRD), and VLS-01, a DMT-based buccal film designed for the same indication. A third candidate, EMP-01, targets social anxiety disorder (SAD).

Analysts at Deutsche Bank highlighted the high unmet need in TRD and the potential for AtaiBeckley’s candidates to deliver rapid and lasting effects. They noted that these assets could follow the commercial path of Spravato while offering advantages over longer-acting options. The bank described EMP-01 as carrying optional upside in its valuation work. A risk-adjusted discounted cash flow analysis in the report suggested the shares trade materially below their base-case worth, with roughly 3.5x upside against a 70% downside scenario.

Data readouts stand out as near-term events. Phase 2 results for VLS-01 are scheduled for the second half of 2026, while additional Phase 2a data for BPL-003 as an add-on to SSRIs with a two-dose schedule are expected in Q4 2026. The company also recently published positive findings from an earlier BPL-003 study in the Journal of Psychopharmacology and gained inclusion in several S&P and CRSP indexes.

This marks the first time a major global investment bank has launched formal coverage on a pure-play psychedelic developer. Other research firms maintain a Strong Buy consensus on AtaiBeckley, with average targets around $13 and a range from $7 to $25.

For the broader psychedelics sector, the move by Deutsche Bank AG reflects steady institutional recognition of clinical progress and the shift toward viewing these compounds as legitimate drug candidates rather than experimental curiosities. Pipeline execution, trial outcomes and eventual regulatory decisions will determine how much of the projected value materializes.